328 related articles for article (PubMed ID: 33505645)
21. Therapy for lower-risk MDS.
Carraway HE; Saygin C
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):426-433. PubMed ID: 33275714
[TBL] [Abstract][Full Text] [Related]
22. The revolution of myelodysplastic syndromes.
Sekeres MA; Bejanyan N
Ther Adv Hematol; 2011 Feb; 2(1):33-43. PubMed ID: 23556074
[TBL] [Abstract][Full Text] [Related]
23. Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study.
Steensma DP; Fenaux P; Van Eygen K; Raza A; Santini V; Germing U; Font P; Diez-Campelo M; Thepot S; Vellenga E; Patnaik MM; Jang JH; Varsos H; Bussolari J; Rose E; Sherman L; Sun L; Wan Y; Dougherty S; Huang F; Feller F; Rizo A; Platzbecker U
J Clin Oncol; 2021 Jan; 39(1):48-56. PubMed ID: 33108243
[TBL] [Abstract][Full Text] [Related]
24. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
25. How we manage adults with myelodysplastic syndrome.
Fenaux P; Platzbecker U; Ades L
Br J Haematol; 2020 Jun; 189(6):1016-1027. PubMed ID: 31568568
[TBL] [Abstract][Full Text] [Related]
26. Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS).
Lucero J; Al-Harbi S; Yee KWL
Curr Oncol; 2023 Jun; 30(7):6177-6196. PubMed ID: 37504319
[TBL] [Abstract][Full Text] [Related]
27. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.
Montalban-Bravo G; Garcia-Manero G
Am J Hematol; 2018 Jan; 93(1):129-147. PubMed ID: 29214694
[TBL] [Abstract][Full Text] [Related]
28. Myelodysplastic syndromes: moving towards personalized management.
Hellström-Lindberg E; Tobiasson M; Greenberg P
Haematologica; 2020 Jul; 105(7):1765-1779. PubMed ID: 32439724
[TBL] [Abstract][Full Text] [Related]
29. Luspatercept: A New Tool for the Treatment of Anemia Related to β-Thalassemia, Myelodysplastic Syndromes and Primary Myelofibrosis.
Hatzimichael E; Timotheatou D; Koumpis E; Benetatos L; Makis A
Diseases; 2022 Oct; 10(4):. PubMed ID: 36278584
[TBL] [Abstract][Full Text] [Related]
30. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Garcia-Manero G
Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
[TBL] [Abstract][Full Text] [Related]
31. Novel therapies in low- and high-risk myelodysplastic syndrome.
Germing U; Schroeder T; Kaivers J; Kündgen A; Kobbe G; Gattermann N
Expert Rev Hematol; 2019 Oct; 12(10):893-908. PubMed ID: 31353975
[No Abstract] [Full Text] [Related]
32. Luspatercept in Myelodysplastic Syndromes: Who and When?
Komrokji RS
Hematol Oncol Clin North Am; 2020 Apr; 34(2):393-400. PubMed ID: 32089218
[TBL] [Abstract][Full Text] [Related]
33. Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study.
Platzbecker U; Götze KS; Kiewe P; Germing U; Mayer K; Radsak M; Wolff T; Chromik J; Sockel K; Oelschlägel U; Haase D; Illmer T; Al-Ali HK; Silling G; Reynolds JG; Zhang X; Attie KM; Shetty JK; Giagounidis A
J Clin Oncol; 2022 Nov; 40(33):3800-3807. PubMed ID: 35998303
[No Abstract] [Full Text] [Related]
34. Treatment of Anemia in Transfusion-Dependent and Non-Transfusion-Dependent Lower-Risk MDS: Current and Emerging Strategies.
Germing U; Oliva EN; Hiwase D; Almeida A
Hemasphere; 2019 Dec; 3(6):e314. PubMed ID: 31976486
[TBL] [Abstract][Full Text] [Related]
35. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.
Sibon D; Cannas G; Baracco F; Prebet T; Vey N; Banos A; Besson C; Corm S; Blanc M; Slama B; Perrier H; Fenaux P; Wattel E;
Br J Haematol; 2012 Mar; 156(5):619-25. PubMed ID: 22211483
[TBL] [Abstract][Full Text] [Related]
36. Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes.
Wang C; Sallman DA
Curr Treat Options Oncol; 2023 May; 24(5):387-408. PubMed ID: 36966266
[TBL] [Abstract][Full Text] [Related]
37. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
Fenaux P; Platzbecker U; Mufti GJ; Garcia-Manero G; Buckstein R; Santini V; Díez-Campelo M; Finelli C; Cazzola M; Ilhan O; Sekeres MA; Falantes JF; Arrizabalaga B; Salvi F; Giai V; Vyas P; Bowen D; Selleslag D; DeZern AE; Jurcic JG; Germing U; Götze KS; Quesnel B; Beyne-Rauzy O; Cluzeau T; Voso MT; Mazure D; Vellenga E; Greenberg PL; Hellström-Lindberg E; Zeidan AM; Adès L; Verma A; Savona MR; Laadem A; Benzohra A; Zhang J; Rampersad A; Dunshee DR; Linde PG; Sherman ML; Komrokji RS; List AF
N Engl J Med; 2020 Jan; 382(2):140-151. PubMed ID: 31914241
[TBL] [Abstract][Full Text] [Related]
38. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors.
Mies A; Platzbecker U
Semin Hematol; 2017 Jul; 54(3):141-146. PubMed ID: 28958287
[TBL] [Abstract][Full Text] [Related]
39. How we treat lower-risk myelodysplastic syndromes.
Fenaux P; Adès L
Blood; 2013 May; 121(21):4280-6. PubMed ID: 23575446
[TBL] [Abstract][Full Text] [Related]
40. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
Garcia-Manero G; Chien KS; Montalban-Bravo G
Am J Hematol; 2020 Nov; 95(11):1399-1420. PubMed ID: 32744763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
